Single User
£4350
PDF
76 pages

Thyroid Cancer Forecast in 21 Major Markets 2018-2028


Thyroid cancer is a cancer originating from follicular or parafollicular thyroid cells. It is a relatively rare cancer, but the most common of the endocrine system. The main clinical split is between differentiated and undifferentiated tumour types, with the majority being well-differentiated.

This report provides the current incident population for thyroid cancer across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Saudi Arabia, South Africa, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current incidence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of thyroid cancer patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of thyroid cancer include:

  • Familial Adenomatous Polyposis
  • Acromegaly
  • Diabetes
  • Multiple endocrine neoplasia syndromes
  • Sipple syndrome

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global thyroid cancer market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the incidence of the subdivided types of thyroid cancer and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific co-morbid conditions on the incident population of thyroid cancer patients.
  • Identification of thyroid cancer patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of thyroid cancer patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • ADDITIONAL DATA AVAILABLE ON REQUEST
  • TOP-LINE INCIDENCE FOR THYROID CANCER
  • FEATURES OF THYROID CANCER PATIENTS
  • PAPILLARY THYROID CANCER PATIENTS
  • COMORBIDITIES OF THYROID CANCER PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. AJCC tumour classification for PTC and FTC
  • Table 2. AJCC tumour classification for MTC
  • Table 3. AJCC tumour classification for ATC
  • Table 4. Incidence of thyroid cancer, total (000s)
  • Table 5. Incidence of thyroid cancer, males (000s)
  • Table 6. Incidence of thyroid cancer, females (000s)
  • Table 7. Patients with thyroid cancer by stage, total (000s)
  • Table 8. Patients with thyroid cancer by type, total (000s)
  • Table 9. Patients with thyroid cancer by lymph node and metastasis status, total (000s)
  • Table 10. Patients with thyroid cancer by solitary/multifocal status, total (000s)
  • Table 11. Papillary thyroid cancer patients with BRAF mutations, total (000s)
  • Table 12. Papillary thyroid cancer patients with KRAS mutations, total (000s)
  • Table 13. Papillary thyroid cancer patients with RET/PTC3 mutations, total (000s)
  • Table 14. Thyroid cancer patients with cachexia, total (000s)
  • Table 15. Abbreviations and acronyms used in the report
  • Table 16. USA incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 17. USA incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 18. Canada incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 19. Canada incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 20. France incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 21. France incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 22. Germany incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 23. Germany incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 24. Italy incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 25. Italy incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 26. Spain incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 27. Spain incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 28. UK incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 29. UK incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 30. Poland incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 31. Poland incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 32. Netherlands incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 33. Netherlands incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 34. Russia incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 35. Russia incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 36. Turkey incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 37. Turkey incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 38. Saudi Arabia incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 39. Saudi Arabia incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 40. South Africa incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 41. South Africa incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 42. Japan incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 43. Japan incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 44. China incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 45. China incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 46. South Korea incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 47. South Korea incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 48. India incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 49. India incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 50. Australia incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 51. Australia incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 52. Brazil incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 53. Brazil incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 54. Mexico incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 55. Mexico incidence of thyroid cancer by 5-yr age cohort, females (000s)
  • Table 56. Argentina incidence of thyroid cancer by 5-yr age cohort, males (000s)
  • Table 57. Argentina incidence of thyroid cancer by 5-yr age cohort, females (000s)
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Netherlands, Poland, Republic of Korea, Russian Federation, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States of America